Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Adding a personalized cancer vaccine to a checkpoint inhibitor lowered the risk of recurrence or metastasis by about half.
Adjuvant immunotherapy can help reduce the likelihood of the skin cancer returning, but is more better or is less more?
A personalized melanoma vaccine enters a Phase III study, while a pancreatic cancer vaccine moves on to Phase II.
Moderna and Merck’s customized neoantigen vaccine plus Keytruda lowered the risk for metastasis or death by 65%.
Since 2020, there has been a nationwide shortage of the bladder cancer therapy Bacillus Calmette Guérin (BCG). Here’s why.
A personalized cancer vaccine plus Keytuda lowered the risk of melanoma coming back after surgery.
Keytruda can activate T cells that harbor latent HIV, a possible step toward a functional cure.
Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.
Another vaccine, from Novavax, was 89% effective in a U.K. trial, but both were less potent against the South African coronavirus mutation.
Keytruda plus chemotherapy reduced the risk of disease progression or death by 35% compared with chemotherapy alone in certain people.
Couric has partnered with Merck to produce a web series about being treated for cancer during the pandemic.
The American Red Cross and the American Cancer Society come together to encourage people to #GiveBloodtoGiveTime.
Enfortumab vedotin plus Keytruda yielded a confirmed response in 71% of participants.
Adding immunotherapy to preoperative chemotherapy increased the likelihood of complete remission.
New immunotherapy option approved for uncommon, aggressive type of lung cancer.
First-line immunotherapy improved overall survival by around 20% to 40%, depending on PD-L1 level.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.